CagriSema
Cagrilintide + Semaglutide Combination
Amino Acids
N/A
Molecular Weight
Combination product
Half-life
~7 days (both components)
Research Score
4.5
Studies
38
Storage
N/A
What is CagriSema?
CagriSema is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (GLP-1 agonist). By targeting two complementary satiety pathways, it achieves superior weight loss compared to either component alone. Phase III trials show it may become the most effective obesity treatment.
Key Benefits & Mechanisms
Superior weight loss to semaglutide alone
Dual satiety pathway activation
Amylin + GLP-1 synergy
Up to 25% weight loss in trials
Improved glycemic control
Reduced food cravings
Once-weekly injection
Research Summary
CagriSema Phase II results showed approximately 15-17% weight loss over 32 weeks, with Phase III REDEFINE trials ongoing showing potentially higher efficacy at full dose. Novo Nordisk expects this to be their next-generation obesity treatment following Wegovy.
Related Peptides
Semaglutide
GLP-1 Receptor Agonist
Semaglutide is a GLP-1 receptor agonist with proven efficacy for weight management and glycemic control. FDA-approved as Ozempic (diabetes) and Wegovy (weight management), it mimics the incretin hormone GLP-1 to regulate appetite and blood sugar.
MetabolicTirzepatide
GIP/GLP-1 Dual Receptor Agonist
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist. FDA-approved as Mounjaro (diabetes) and Zepbound (weight management). It offers superior weight loss compared to GLP-1-only agonists by targeting two incretin pathways simultaneously.
MetabolicAOD-9604
Anti-Obesity Drug (Modified GH Fragment)
AOD-9604 is a modified fragment of human growth hormone (HGH fragment 177-191) specifically designed for fat metabolism. It stimulates lipolysis and inhibits lipogenesis without affecting blood sugar or tissue growth, making it a targeted fat-loss peptide without typical GH side effects.
MetabolicTesamorelin
Synthetic Growth Hormone Releasing Hormone
Tesamorelin is an FDA-approved synthetic analog of growth hormone-releasing hormone (GHRH). Approved as Egrifta for HIV-associated lipodystrophy, it reduces visceral adipose tissue while maintaining peripheral fat and improving body composition. Produces physiological GH release.
Metabolic